Select country set
Menu Shopping cart 0,00 Search
Distributed product

Apo B-48 Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Apolipoprotein B-48
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

637-10641 96 wells (1 kit)
PubMed Product Details
Technical Data

Cat # changed from RSHAKHB48R to 637-10641


Sandwich ELISA, Biotin-labelled antibody


Serum, Plasma-EDTA, Plasma-Heparin

Sample Requirements

50 µl/well (Diluted to 100X with buffer solution ©)


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

2.5–160 ng/ml

Limit of Detection

0.198 ng/ml

Intra-assay (Within-Run)

n = 5; CV = 3.5%

Inter-assay (Run-to-Run)

n = 3; CV = 5.7%

Spiking Recovery

99.9 %



  • This is intended for research use only.
  • Rapid assay (total reaction time: 2 h 50min.).
  • This kit is for apolipoprotein B-48 in human serum or plasma (citric acid for plasma is not suitable).
  • A small sample volume of serum or plasma (5 µl) is needed.
  • Assay format is 96 wells.
  • Standard Apo B-48 is derived from human.

Research topic

Cardiovascular disease, Energy metabolism and body weight regulation, Lipoprotein metabolism


Plasma lipoproteins are complex substances composed of certain ratios of lipids and proteins, and are important factors for serum lipids transportation. On the surface of the lipoprotein structure, apolipoproteins are present and playing roles in stabilization of lipoprotein structure, in activation of enzymes relating to lipoprotein metabolism, and in binding with lipoprotein receptors on the cell surface. Apolipoprotein-B48 (ApoB-48) has 48% amino acid sequence of apolipoprotein B-100 which is present in lipoproteins ,VLDL, LDL and HDL of liver origin. ApoB-48 is an apolipoprotein specific to a lipoprotein, chylomicron (CM) which is formed in intestine and carries exogenous lipids derived from foods to the liver and peripheral tissues. Measurement of ApoB-48 is useful in observation and pursuit of postprandial dynamics of lipoprotein, lipid-soluble nutrients and drugs.

Product References (22)


  • Akiyama S, Katsumata S, Suzuki K, Ishimi Y, Wu J, Uehara M. Dietary hesperidinexerts hypoglycemic and hypolipidemic effects in streptozotocin-induced marginal type 1 diabetic rats. J Clin Biochem Nutr. 2010 Jan;46(1):87-92. doi:10.3164/jcbn.09-82. Epub 2009 Dec 29. PubMed PMID: 20104270; PubMed CentralPMCID: PMC2803138. See more on PubMed
  • Akiyama S, Katsumata S, Suzuki K, Nakaya Y, Ishimi Y, Uehara M. Hypoglycemicand hypolipidemic effects of hesperidin and cyclodextrin-clathrated hesperetin inGoto-Kakizaki rats with type 2 diabetes. Biosci Biotechnol Biochem. 2009Dec;73(12):2779-82. Epub 2009 Dec 7. PubMed PMID: 19966469. See more on PubMed
  • Beigneux AP, Franssen R, Bensadoun A, Gin P, Melford K, Peter J, Walzem RL,Weinstein MM, Davies BS, Kuivenhoven JA, Kastelein JJ, Fong LG, Dallinga-Thie GM,Young SG. Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bindlipoprotein lipase. Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):956-62. doi:10.1161/ATVBAHA.109.186577. Epub 2009 Mar 19. PubMed PMID: 19304573; PubMedCentral PMCID: PMC2811263. See more on PubMed
  • Castro Cabezas M, Erkelens DW, Kock LA, De Bruin TW. Postprandialapolipoprotein B100 and B48 metabolism in familial combined hyperlipidaemiabefore and after reduction of fasting plasma triglycerides. Eur J Clin Invest.1994 Oct;24(10):669-78. PubMed PMID: 7851467. See more on PubMed
  • Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastricemptying in subjects with obesity. Diabetes Obes Metab. 2018 Mar;20(3):610-619.doi: 10.1111/dom.13120. Epub 2017 Oct 27. PubMed PMID: 28941314; PubMed CentralPMCID: PMC5836914. See more on PubMed
  • Kinoshita M, Kojima M, Matsushima T, Teramoto T. Determination ofapolipoprotein B-48 in serum by a sandwich ELISA. Clin Chim Acta. 2005Jan;351(1-2):115-20. PubMed PMID: 15563879. See more on PubMed
  • Lamon-Fava S, Diffenderfer MR, Barrett PH, Buchsbaum A, Nyaku M, Horvath KV,Asztalos BF, Otokozawa S, Ai M, Matthan NR, Lichtenstein AH, Dolnikowski GG,Schaefer EJ. Extended-release niacin alters the metabolism of plasmaapolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler ThrombVasc Biol. 2008 Sep;28(9):1672-8. doi: 10.1161/ATVBAHA.108.164541. Epub 2008 Jun 19. PubMed PMID: 18566298; PubMed Central PMCID: PMC2761712. See more on PubMed
  • Lekhal S, Børvik T, Nordøy A, Hansen JB. Decreased lipoprotein lipase activityand increased postprandial concentrations of triglyceride-rich lipoproteins inoffspring of elderly survivors of myocardial infarction. Nutr Metab CardiovascDis. 2008 Dec;18(10):700-6. doi: 10.1016/j.numecd.2007.10.001. Epub 2008 Jan 14. PubMed PMID: 18194851. See more on PubMed
  • Nakajima K, Nakajima Y, Takeichi S, Fujita MQ. ApoB-100 carrying lipoprotein, but not apoB-48, is the major subset of proatherogenic remnant-like lipoproteinparticles detected in plasma of sudden cardiac death cases. Atherosclerosis. 2007Oct;194(2):473-82. Epub 2006 Oct 11. PubMed PMID: 17045270. See more on PubMed
  • Nakano T, Nakajima K, Niimi M, Fujita MQ, Nakajima Y, Takeichi S, Kinoshita M,Matsushima T, Teramoto T, Tanaka A. Detection of apolipoproteins B-48 and B-100carrying particles in lipoprotein fractions extracted from human aorticatherosclerotic plaques in sudden cardiac death cases. Clin Chim Acta. 2008Apr;390(1-2):38-43. doi: 10.1016/j.cca.2007.12.012. Epub 2007 Dec 23. PubMedPMID: 18206113. See more on PubMed
  • Nakano T, Shimanuki T, Matsushita M, Koyama I, Inoue I, Katayama S, Alpers DH,Komoda T. Involvement of intestinal alkaline phosphatase in serum apolipoprotein B-48 level and its association with ABO and secretor blood group types. BiochemBiophys Res Commun. 2006 Mar 3;341(1):33-8. Epub 2006 Jan 5. PubMed PMID:16412386. See more on PubMed
  • Nakano T, Tanaka A, Okazaki M, Tokita Y, Nagamine T, Nakajima K. Particle sizeof apoB-48 carrying lipoproteins in remnant lipoproteins isolated frompostprandial plasma. Ann Clin Biochem. 2011 Jan;48(Pt 1):57-64. doi:10.1258/acb.2010.010193. Epub 2010 Nov 23. PubMed PMID: 21098545. See more on PubMed
  • Otokozawa S, Ai M, Diffenderfer MR, Asztalos BF, Tanaka A, Lamon-Fava S,Schaefer EJ. Fasting and postprandial apolipoprotein B-48 levels in healthy,obese, and hyperlipidemic subjects. Metabolism. 2009 Nov;58(11):1536-42. doi:10.1016/j.metabol.2009.04.040. Epub 2009 Jul 9. PubMed PMID: 19592048; PubMedCentral PMCID: PMC4565183. See more on PubMed
  • Otokozawa S, Ai M, Van Himbergen T, Asztalos BF, Tanaka A, Stein EA, Jones PH,Schaefer EJ. Effects of intensive atorvastatin and rosuvastatin treatment onapolipoprotein B-48 and remnant lipoprotein cholesterol levels. Atherosclerosis. 2009 Jul;205(1):197-201. doi: 10.1016/j.atherosclerosis.2008.11.001. Epub 2008Nov 12. PubMed PMID: 19200542; PubMed Central PMCID: PMC4565182. See more on PubMed
  • Saito S, Yamaguchi T, Shoji K, Hibi M, Sugita T, Takase H. Effect of lowconcentration of diacylglycerol on mildly postprandial hypertriglyceridemia.Atherosclerosis. 2010 Dec;213(2):539-44. doi:10.1016/j.atherosclerosis.2010.07.062. Epub 2010 Aug 19. PubMed PMID: 20837352. See more on PubMed
  • Soriguer F, García-Serrano S, Garrido-Sánchez L, Gutierrez-Repiso C,Rojo-Martínez G, Garcia-Escobar E, García-Arnés J, Gallego-Perales JL, Delgado V,García-Fuentes E. Jejunal wall triglyceride concentration of morbidly obesepersons is lower in those with type 2 diabetes mellitus. J Lipid Res. 2010Dec;51(12):3516-23. doi: 10.1194/jlr.M007815. Epub 2010 Sep 20. PubMed PMID:20855567; PubMed Central PMCID: PMC2975724. See more on PubMed
  • Teramoto T. Postprandial hyperlipidemia and atherosclerosis. Curr Atheroscler Rep. 2007 Sep;9(3):169-70. PubMed PMID: 18241608. See more on PubMed
  • Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect ofsitagliptin therapy on postprandial lipoprotein levels in patients with type 2diabetes. Diabetes Obes Metab. 2011 Apr;13(4):366-73. doi:10.1111/j.1463-1326.2011.01362.x. PubMed PMID: 21226820. See more on PubMed
  • Tremblay AJ, Lamarche B, Lemelin V, Hoos L, Benjannet S, Seidah NG, Davis HRJr, Couture P. Atorvastatin increases intestinal expression of NPC1L1 inhyperlipidemic men. J Lipid Res. 2011 Mar;52(3):558-65. doi: 10.1194/jlr.M011080.Epub 2010 Dec 1. PubMed PMID: 21123766; PubMed Central PMCID: PMC3035692. See more on PubMed
  • Valdivielso P, Puerta S, Rioja J, Alonso I, Ariza MJ, Sánchez-Chaparro MA,Palacios R, González-Santos P. Postprandial apolipoprotein B48 is associated withasymptomatic peripheral arterial disease: a study in patients with type 2diabetes and controls. Clin Chim Acta. 2010 Mar;411(5-6):433-7. doi:10.1016/j.cca.2009.12.022. Epub 2010 Jan 6. PubMed PMID: 20059992. See more on PubMed
  • Valdivielso P, Rioja J, García-Arias C, Sánchez-Chaparro MA, González-SantosP. Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when addedto fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: apreliminary report. Cardiovasc Diabetol. 2009 Jan 8;8:1. doi:10.1186/1475-2840-8-1. PubMed PMID: 19133114; PubMed Central PMCID: PMC2631503. See more on PubMed
  • van Himbergen TM, Otokozawa S, Matthan NR, Schaefer EJ, Buchsbaum A, Ai M, vanTits LJ, de Graaf J, Stalenhoef AF. Familial combined hyperlipidemia isassociated with alterations in the cholesterol synthesis pathway. ArteriosclerThromb Vasc Biol. 2010 Jan;30(1):113-20. doi: 10.1161/ATVBAHA.109.196550. Epub2009 Oct 15. PubMed PMID: 19834104; PubMed Central PMCID: PMC2813691. See more on PubMed
Related Products Docs